1-7 of 7
Cecilia Yeung
Close
Sort by
Journal Articles

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Mazyar Shadman, Cecilia Yeung, Mary Redman, Sang Yun Lee, Dong Hoon Lee, Susan Ra, Chaitra S. Ujjani, Bruce J. Dezube, Christina Poh, Edus H. Warren, Aude G. Chapuis, Damian J. Green, Andrew J. Cowan, Ryan D. Cassaday, Hans-Peter Kiem, Jordan Gauthier, Cameron J. Turtle, Ryan C. Lynch, Stephen D. Smith, Ajay K Gopal, David G. Maloney, Brian G. Till
Journal: Blood
Blood (2021) 138 (Supplement 1): 3872.
https://doi.org/10.1182/blood-2021-149181
Published: 2021
Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Mazyar Shadman, MDMPH, Cecilia Yeung, MD, Mary W Redman, PhD, Sang Yun Lee, PhD, Dong Hoon Lee, B.S., Ajeetha Ramachandran, PhD, Susan Ra, BS, Edmond A Marzbani, MD, Solomon A. Graf, MD, Edus H. Warren, MD PhD, Ajay K. Gopal, MD, Aude G. Chapuis, MD, Merav Bar, Damian J. Green, MD, Jordan Gauthier, MD MSc, Ryan D. Cassaday, MD, Hans-Peter Kiem, MD PhD, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Brian G. Till, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-136440
Published: 2020
Journal Articles

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Mazyar Shadman, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Cameron J. Turtle, MBBS, PhD, Adam Greenbaum, MD PhD, Mary Redman, Cecilia Yeung, MD, Martina Sersch, MD PhD, Edus H. Warren, MD PhD, David G. Maloney, MD PhD, Brian G. Till, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3235.
https://doi.org/10.1182/blood-2019-125102
Published: 2019
Journal Articles

New approaches to molecular monitoring in CML (and other diseases)

Jerald Radich, Cecilia Yeung, David Wu
Journal: Blood
Blood (2019) 134 (19): 1578–1584.
https://doi.org/10.1182/blood.2019000838
Published: 2019
Journal Articles

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Cameron J. Turtle, MBBS, PhD, Kevin A. Hay, MD FRCPC, MSc, Laila-Aicha Hanafi, PhD, Juliane Gust, MDPhD, W. Conrad Liles, MDPhD, José A. López, MD, Junmei Chen, PhD, Dominic W. Chung, PhD, Mark M Wurfel, MDPhD, Susanna Harju-Baker, PhD, Hasan Ozpolat, MD, Daniel Li, PhD, David Myerson, MDPhD, Luis F. Gonzalez-Cuyar, MD, Cecilia Yeung, MD, Kathleen R. Fink, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 805.
https://doi.org/10.1182/blood.V130.Suppl_1.805.805
Published: 2017
Journal Articles

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Bronwyn H. Bryant, MD, Cecilia Yeung, MD, Brian G. Till, MD, Stephen D. Smith, MD, Edward N. Libby, MD, Andrei R. Shustov, MD, John M. Pagel, MD PhD, Damian J. Green, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Min Fang, MD PhD, Leona Holmberg, MD PhD, William I. Bensinger, MD, David G Maloney, MDPhD, Ajay K. Gopal, MD, Oliver W. Press, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1731.
https://doi.org/10.1182/blood.V124.21.1731.1731
Published: 2014
Journal Articles

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Ekapun Karoopongse, MD, John Byon, MD, PhD, Cecilia Yeung, MD, H. Joachim Deeg, MD, A. Mario Q. Marcondes, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1543.
https://doi.org/10.1182/blood.V122.21.1543.1543
Published: 2013